← All indications
Rectal Neoplasms
Tumors or cancer of the RECTUM.
Subtype terms (1)
More specific conditions that are subtypes of Rectal Neoplasms in the MeSH hierarchy.
- Anus Neoplasms
70 drugs (41 approved, 29 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (24)
Phase 3 trials (36)
- ringer's lactate
- epoetin
- irinotecan
- anx-510
- tamsulosin
- fruquintinib
- paclitaxel
- Filgrastim
- nivolumab
- indocyanine green
- mitomycin
- carboplatin
- rifaximin
- celecoxib
- sgm-101
- bevacizumab
- abiraterone
- uracil
- vsl #3
- sildenafil
- vatalanib
- tipiracil
- tegafur
- Ferumoxtran
- loperamide
- xelox
- camrelizumab
- interferon alpha-2b
- sintilimab
- hlx10
- +6 more
Phase 2 trials (137)
- ino-3112
- fluorothymidine
- hx4
- 64cu-atsm
- 5,10-methylene-5,6,7,8-tetrahydrofolate
- anlotinib
- rilotumumab
- amifostine
- atezolizumab
- autologous tumor infiltrating lymphocytes
- avelumab
- urea
- bi 754091
- bi 836880
- bmx-001
- propylformic acid
- cb-839
- cixutumumab
- conatumumab
- creatinine
- it-101
- mk-0646
- valproic acid
- durvalumab
- e7 tcr transduced pbl cells
- e7820
- cannabidiol
- ganitumab
- gemcitabine
- mesalamine
- +107 more
Phase 1 trials (44)
- nitroglycerin
- 7-hydroxystaurosporine
- prexasertib
- allogeneic natural killer cells
- brodalumab
- astx660
- sorafenib
- mkc1106
- lenalidomide
- selinexor
- doxorubicin
- hpv specific t cells
- Imetelstat
- lenvatinib
- talaporfin
- mage-12 peptide vaccine
- montanide isa51
- alpelisib
- prostate specific membrane antigen
- interleukin-12
- tg02
- topotecan
- vorinostat
- fluorodeoxythymidine
- clostridium butyricum
- cediranib
- sodium thiosulfate
- selumetinib
- umbralisib
- anakinra
- +14 more
Other trials (28)
- maltodextrin
- vitamin d3
- gadofosveset trisodium
- whey protein
- pimonidazole
- technetium tc-99m sulfur colloid kit
- human peritoneal membrane
- autologous microbiome
- cu 64 m5a
- oat bran
- cefoperazone
- midazolam
- corn
- formaldehyde
- erythromycin
- omega-3 fatty acids
- blueberry
- fluoromisonidazole
- polyethylene glycol
- 68ga-fapi-04
- formyltetrahydrofolate
- [18f]f-resca-rb14
- [18f]f-resca-t4
- [68ga]ga-dota-h2d3
- [68ga]ga-nota-t4
- [68ga]ga-nota-g5
- [68ga]ga-nota-rnd20
- [68ga]ga-nota-wwh347
Organizations
Organization Involved with Phase 4 Indications (18)
- J. Uriach and Company
- University of Illinois
- Hospital de Granollers
- Lund University
- Seoul National University
- Sundsvall Hospital
- Wroclaw Medical University
- Peking University
- University of Ulm
- Uppsala University
- Orebro University
- Kyungpook University
- Linkoping University
- OSF HealthCare
- Kalmar County Hospital
- Helsingborgs Hospital
- Pharmbio Korea
- University of Helsinki
Organization Involved with Phase 3 Indications (104)
- Roche
- Merck
- Novartis
- Bayer
- Corporacion Parc Tauli
- Ortho Biotech, Inc.
- Ortho Pharmaceuticals
- Surgimab
- Medical Research Council
- National Cancer Institute (NCI)
- Aarhus University
- Maastricht University
- Blokhin's Russian Cancer Research Center
- Canadian Cancer Trials Group
- Cancer and Leukemia Group B (CALGB)
- Cancer Research UK
- Centre Leon Berard
- University of London
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- ECOG-ACRIN Cancer Research Group
- Federation Francophone de Cancerologie Digestive
- Harbin Medical University
- Deutsche Krebshilfe e.V.
- Institut de Cancérologie de Lorraine
- Institut Paoli-Calmettes
- Katholieke Universiteit Leuven
- King Faisal University
- Jilin Provincial Tumor Hospital
- +74 more
Organization Involved with Phase 2 Indications (213)
- Incyte
- Eisai
- Bristol-Myers Squibb
- Amgen
- Servier
- Biocompatibles International plc
- Imclone
- Immunomedics
- AstraZeneca
- Merck Serono
- Eli Lilly
- Genentech
- Merck KGaA
- Pfizer
- Sanofi
- Siemens
- Wyeth
- AIO-Studien-gGmbH
- Allergan
- Array BioPharma
- CTC Bio, Inc.
- DSM
- GenVec
- Loma Linda Oncology Medical Group, Inc.
- Ozmosis Research Inc.
- Synta Pharmaceuticals Corp.
- Boehringer Ingelheim
- Generic Devices Consulting, Inc.
- Isofol Medical AB
- Otsuka
- +183 more
Organization Involved with Phase 1 Indications (18)
- AbbVie
- Millennium Pharmaceuticals
- GlaxoSmithKline
- Karyopharm Therapeutics Inc
- PsiOxus Therapeutics Ltd
- The Christie NHS Foundation Trust
- Case Western Reserve University
- Emory University
- University of Groningen
- University of Lausanne
- Virginia Commonwealth University
- Wake Forest University
- University of California, Davis
- University of Wisconsin
- University of Alabama, Birmingham
- Department of Veteran Affairs
- Dutch Cancer Society
- Taiho Pharmaceutical
Organization Involved with Other Experimental Indications (16)
- Region Skane
- Grupo Hospital de Madrid
- Portuguese Oncology Institute, Coimbra
- Yale University
- University of Connecticut
- CJ HealthCare Corp.
- Government of Russia
- University of Sao Paulo
- Centro Integral Oncológica Clara Campal
- Jackson Laboratory
- Ente Ospedaliero Cantonale
- American Cancer Society, Inc.
- California Walnut Commission
- Hospital A.C. Camargo
- Aran Biomedical
- American Institute for Cancer Research (AICR)